The pCODR does not recommend the funding of aflibercept when used in combinaiton with an irinotecan and a fluoropyrimidine (FOLFIRI) based therapy for patients with metastatic colorectal cancer previouusly treated with an oxaliplatin-containind regimen.  The Committee made this initial recommendation because compared with placebo and FOLFIRI, aflibercept plus FOLFIRI had only a very modest effect on overall survival and progression-free survival. It also has significant toxicities and its effect on health-related quality of life is unknown. As yet, no date has been set for its reconsideration by the pCODR.

For more details, go to: http://www.pcodr.ca/wcpc/portal/Home/FindaReview/ZaltrapmCRC?_afrLoop=1279164391261914&lang=en&_afrWindowMode=0&_adf.ctrl-state=b0bp9ruk8_91